Mivebresib

• CAT Number: I001714
• CAS Number: 1445993-26-9
• Molecular Formula: C₂₂H₁₉F₂N₃O₄S
• Molecular Weight: 459.47
• Purity: ≥95%
• Target: target: BET, MYC
• Solubility: DMSO ≥ 37 mg/mL
• Storage: -20°C
• IUPAC Name: N-[4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl]ethanesulfonamide
• InChI: InChI=1S/C22H19F2N3O4S/c1-3-32(29,30)26-14-5-7-19(31-20-6-4-13(23)10-18(20)24)16(11-14)17-12-27(2)22(28)21-15(17)8-9-25-21/h4-12,25-26H,3H2,1-2H3
• InChIKey: RDONXGFGWSSFMY-UHFFFAOYSA-N
• SMILES: CCS(=O)(=O)NC1=CC(=C(C=C1)OC2=C(C=C(C=C2)F)F)C3=CN(C(=O)C4=C3C=CN4)C

Mivebresib (Cat No.:I001714) is a novel inhibitor that targets the BET family of bromodomains. It demonstrates high affinity binding to the bromodomain of BRD2/4/T (with Ki values between 1-2.2 nM) and exhibits selectivity. While it has lower potency against BRD3 (Ki=12.2 nM), it shows moderate activity against CREBBP (Ki=87 μM). Mivebresib effectively induces apoptosis in various tumor cells, making it a promising compound for potential anticancer treatments.

Reference

[1]. EJ Faivre et al. Abstract 4694: ABBV-075, a novel BET family inhibitor, disrupts critical transcription programs that drive prostate cancer growth to induce potent anti-tumor activity in vitro and in vivo